The demand for GLP-1s isnt just about filling prescriptions
Frequently Asked Questions Why does the article say oral liquid formulations are taken on an empty stomach
The replies are more individualized than the boilerplate-only responses we see at lower-graded clinics, but the templated opener stands out
The following search algorithm was applied: ((GLP-1 receptor agonist OR glucagon-like peptide-1 receptor agonist OR GIP receptor agonist OR glucose-dependent insulinotropic polypeptide OR liraglutide OR semaglutide OR dulaglutide OR tirzepatide) AND (body composition OR fat mass OR muscle mass OR lean mass OR adiposity OR body fat OR sarcopenia)) AND (clinical trial OR study OR randomized controlled trial OR RCT OR intervention study)
The validity of major CI diagnoses in the Danish National Patient Register has been previously assessed and it was found to have positive predictive values more than 80% [17, 18]
A total of 577 patients were randomly assigned (1:1:1) to receive once-weekly dulaglutide (1.5 mg), once-weekly dulaglutide (0.75 mg), or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks
